Ollo Roland Somé^1,*, Abdoul Halim Bagué², Damien Konkobo¹, Dieudonné Hien³, Adama Dembélé³, GL Hermann Bélemlilga¹, Valentin Konségré⁴, Nayi Zongo⁵

Oncologie, Vol.24, No.2, pp. 173-184, 2022, DOI:10.32604/oncologie.2022.021250

Abstract Introduction: Breast cancer management in Sub-Saharian Africa, is faced with diagnosis and treatment challenges. This study aims to describe, breast cancers epidemiology in Bobo-Dioulasso, Burkina Faso. Patients and method: A retrospective cohort study was performed from July 01, 2015 to December 31, 2021 in the Souro Sanou university teaching hospital. Histologically confirmed breast cancer patients were included. Clinical aspect, treatment features and outcome data were collected and analyzed. Results: In study time, eight male’s cases (2%) 360 female’s cases among 368 breast cancers cases were included. The mean age was 46.6 ± 12.1 years, ranging from 15 to… More >

E. du Rouchet, C. Dendoncker

Oncologie, Vol.21, No.2, pp. 125-134, 2019, DOI:10.3166/onco-2019-0042

Abstract For a patient suffering from breast cancer, access to the initial treatment includes several steps like confirmation of an anatomopathological diagnosis, proposition and establishment of an individualized treatment plan, pretreatment assessments, and access to the technical platform. The accumulated duration of these intervals plays a role in the prognosis in the early stages of the disease. In addition, it is important to manage all the uncertainties, both diagnostic and prognostic, which will inevitably upset the patient’s psychological balance. Supported by literature, recommendations and more than 20 years of experience in a multidisciplinary centre, the authors… More >

V. Allouchery, L. Augusto, F. Clatot

Oncologie, Vol.21, No.1, pp. 40-48, 2019, DOI:10.3166/onco-2019-0035

Abstract It has been known for a long time that circulating tumor cells (CTC) as well as circulating tumor DNA (ctDNA) can be detected. However, only recent technical advances allowed evaluating the interest of CTC and ctDNA in breast cancer. In both early and metastatic breast cancers, CTC detection is a recognized factor for poor outcome. Nevertheless, CTC detection does not impact cancer management yet. The use of ctDNA in daily practice will require validation by prospective data. But ctDNA seems particularly promising both for residual disease evaluation and identification of tumor clones harbouring mutations (PI3KC, ESR1)… More >

Delphine Déniel Lagadec^1,2,*, Laurence Guen^1,2, Fabienne Le Goc Le Sager¹, Sandrine Estivin^1,3, Christophe Perrin^1,4

Oncologie, Vol.23, No.1, pp. 39-46, 2021, DOI:10.32604/Oncologie.2021.015985

Abstract Depuis mars 2020, l’épidémie de la COVID-19 impacte la prise en charge des patients dans le secteur de l’oncologie/hématologie dans les établissements de santé publics et privés. L’Unité de Coordination en Onco-Gériatrie région Bretagne a initié une enquête auprès des spécialistes en cancérologie afin de faire un état des lieux sur la prise en charge des patients atteints de cancer et âgés de plus de 75 ans dans la région. L’enquête a étéréalisée courant octobre 2020, post premier confinement, auprès de 24 spécialistes. 67% des spécialistes ont le sentiment de manquer de consignes claires/protocoles institutionnels More >

Sophie Piperno-Neumann^1,*, Pascale Mariani², Vincent Servois³, Gaelle Pierron⁴, Livia LumbrosoRouic⁵, Alexandre Matet^5,6, Manuel Rodrigues¹, Nathalie Cassoux^5,6

Oncologie, Vol.22, No.4, pp. 203-212, 2020, DOI:10.32604/oncologie.2020.014102

Abstract Le mélanome de l’uvée est un cancer rare, en tous points différent du mélanome cutané. Malgré un excellent contrôle local grâce aux traitements ophtalmologiques, 20 à 50% des patients développent des métastases, hépatiques le plus souvent, dont le pronostic est sombre et la survie médiane de 12 mois, en l’absence de traitement systémique efficace et en dehors des rares cas relevant de la chirurgie. Une meilleure connaissance de la biologie et une recherche préclinique dédiée sont les éléments indispensables à une recherche clinique basée sur l’identification de cibles thérapeutiques spécifiques du mélanome uvéal. More >